Cyp2c66 (cytochrome P450, family 2, subfamily c, polypeptide 66) - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)
Gene: Cyp2c66 (cytochrome P450, family 2, subfamily c, polypeptide 66) Mus musculus
Analyze
Symbol: Cyp2c66
Name: cytochrome P450, family 2, subfamily c, polypeptide 66
RGD ID: 1616754
MGI Page MGI
Description: Predicted to enable caffeine oxidase activity; heme binding activity; and monooxygenase activity. Acts upstream of or within hematopoietic progenitor cell differentiation. Predicted to be located in plasma membrane. Predicted to be active in cytoplasm and intracellular membrane-bounded organelle. Human ortholog(s) of this gene implicated in end stage renal disease and renal hypertension. Orthologous to human CYP2C8 (cytochrome P450 family 2 subfamily C member 8).
Type: protein-coding
RefSeq Status: PROVISIONAL
Previously known as: 2010301M18Rik; cytochrome P450, 2c66
RGD Orthologs
Rat
Alliance Orthologs
More Info more info ...
Related Pseudogenes: Cyp2c73-ps  
Latest Assembly: GRCm39 - Mouse Genome Assembly GRCm39
Position:
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCm391939,102,342 - 39,175,200 (+)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl1939,102,342 - 39,175,516 (+)EnsemblGRCm39 Ensembl
GRCm381939,113,898 - 39,186,756 (+)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl1939,113,898 - 39,187,072 (+)EnsemblGRCm38mm10GRCm38
MGSCv371939,188,388 - 39,261,246 (+)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv361939,178,942 - 39,240,067 (+)NCBIMGSCv36mm8
Celera1939,916,729 - 39,978,061 (+)NCBICelera
Cytogenetic Map19C3NCBI
cM Map1933.75NCBI
JBrowse: View Region in Genome Browser (JBrowse)
Model


1 to 9 of 9 rows

  
Object Symbol
Species
Term
Qualifier
Evidence
With
Reference
Notes
Source
Original Reference(s)
Cyp2c66MouseAllergic Rhinoconjunctivitis treatmentISOCYP2C19 (Homo sapiens)11352743associated with Eosinophilic Esophagitis and DNA:polymorphisms::RGD 
Cyp2c66MouseDrug Eruptions susceptibilityISOCYP2C19 (Homo sapiens)11352742DNA:SNP: :Rs4244285(human)RGD 
Cyp2c66Mouseend stage renal disease  ISOCYP2C8 (Homo sapiens)7243146DNA:polymorphisms: :RGD 
Cyp2c66Mouseeosinophilic esophagitis treatmentISOCYP2C19 (Homo sapiens)11352743DNA:polymorphisms::RGD 
Cyp2c66MouseHematologic Neoplasms treatmentISOCYP2C19 (Homo sapiens)11352750DNA:polymorphism: :RGD 
Cyp2c66Mousemultiple myeloma no_associationISOCYP2C19 (Homo sapiens)11352804DNA:polymorphisms: :RGD 
Cyp2c66Mousemultiple myeloma treatmentISOCYP2C19 (Homo sapiens)11352748DNA:polymorphisms: :RGD 
Cyp2c66Mouserenal hypertension  ISOCYP2C8 (Homo sapiens)7243143 RGD 
Cyp2c66Mousesickle cell anemia susceptibilityISOCYP2C19 (Homo sapiens)11352749DNA:polymorphisms: :c.681 G>A and wildtype(human)RGD 
1 to 9 of 9 rows

1 to 20 of 20 rows

  
Object Symbol
Species
Term
Qualifier
Evidence
With
Reference
Notes
Source
Original Reference(s)
Cyp2c66Mouse1,2-dichloroethane increases expressionEXP 6480464ethylene dichloride results in increased expression of CYP2C66 mRNACTDPMID:28960355
Cyp2c66Mouse1,2-dimethylhydrazine decreases expressionEXP 64804641 and 2-Dimethylhydrazine results in decreased expression of CYP2C66 mRNACTDPMID:22206623
Cyp2c66Mouse1,2-dimethylhydrazine multiple interactionsEXP 6480464[1 and 2-Dimethylhydrazine co-treated with Folic Acid] results in decreased expression of CYP2C66 mRNACTDPMID:22206623
Cyp2c66Mouse4-hydroxytolbutamide multiple interactionsEXP 6480464[CYP2C66 protein results in increased metabolism of Tolbutamide] which results in increased chemical synthesis of 4'-hydroxytolbutamideCTDPMID:30503582
Cyp2c66MouseAzoxymethane multiple interactionsEXP 6480464[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C66 mRNACTDPMID:29950665
Cyp2c66Mousebenzo[a]pyrene increases expressionEXP 6480464Benzo(a)pyrene results in increased expression of CYP2C66 mRNACTDPMID:20127859
Cyp2c66Mousecannabidiol multiple interactionsEXP 6480464[Plant Extracts results in increased abundance of Cannabidiol] which results in increased expression of CYP2C66 mRNACTDPMID:33096940
Cyp2c66Mousecarnosic acid decreases expressionEXP 6480464salvin results in decreased expression of CYP2C66 proteinCTDPMID:35926579
Cyp2c66Mousecholine multiple interactionsEXP 6480464[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of CYP2C66 mRNACTDPMID:20938992
Cyp2c66Mousedextran sulfate multiple interactionsEXP 6480464[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C66 mRNACTDPMID:29950665
Cyp2c66Mousefolic acid multiple interactionsEXP 6480464[1 more ...CTDPMID:20938992 and PMID:22206623
Cyp2c66Mouseinulin multiple interactionsEXP 6480464[perfluorooctane sulfonic acid co-treated with Inulin] results in increased expression of CYP2C66 mRNACTDPMID:36331819
Cyp2c66MouseL-methionine multiple interactionsEXP 6480464[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of CYP2C66 mRNACTDPMID:20938992
Cyp2c66Mousemonosodium L-glutamate increases expressionEXP 6480464Sodium Glutamate results in increased expression of CYP2C66 mRNACTDPMID:20111022
Cyp2c66Mousemonosodium L-glutamate multiple interactionsEXP 6480464[Sodium Glutamate co-treated with High Fructose Corn Syrup] results in increased expression of CYP2C66 mRNACTDPMID:20111022
Cyp2c66Mouseperfluorooctane-1-sulfonic acid multiple interactionsEXP 6480464[perfluorooctane sulfonic acid co-treated with Inulin] results in increased expression of CYP2C66 mRNACTDPMID:36331819
Cyp2c66Mousetitanium dioxide multiple interactionsEXP 6480464[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C66 mRNACTDPMID:29950665
Cyp2c66Mousetolbutamide increases metabolic processingEXP 6480464CYP2C66 protein results in increased metabolism of TolbutamideCTDPMID:30503582
Cyp2c66Mousetolbutamide multiple interactionsEXP 6480464[CYP2C66 protein results in increased metabolism of Tolbutamide] which results in increased chemical synthesis of 4'-hydroxytolbutamideCTDPMID:30503582
Cyp2c66Mousevalproic acid affects expressionEXP 6480464Valproic Acid affects the expression of CYP2C66 mRNACTDPMID:17963808

1 to 20 of 20 rows

Biological Process

  
Object Symbol
Species
Term
Qualifier
Evidence
With
Reference
Notes
Source
Original Reference(s)
Cyp2c66Mousehematopoietic progenitor cell differentiation acts_upstream_of_or_withinIGIMGI:13431842290270 PMID:24029230MGIPMID:24029230
Cyp2c66Mouseorganic acid metabolic process involved_inIBAPANTHER:PTN000670347 more ...2290270 GO_CentralGO_REF:0000033
Cyp2c66Mousexenobiotic metabolic process involved_inIBAPANTHER:PTN000670347 more ...2290270 GO_CentralGO_REF:0000033

Cellular Component

  
Object Symbol
Species
Term
Qualifier
Evidence
With
Reference
Notes
Source
Original Reference(s)
Cyp2c66Mousecytoplasm is_active_inIBAPANTHER:PTN000670347 more ...2290270 GO_CentralGO_REF:0000033
Cyp2c66Mouseplasma membrane located_inISOUniProtKB:P10632 and UniProtKB:P117122290270 GO_CentralGO_REF:0000119

Molecular Function
1 to 9 of 9 rows

  
1 to 9 of 9 rows

Imported Annotations - SMPDB

1 to 19 of 19 rows
Object Symbol
Species
Term
Qualifier
Evidence
With
Reference
Notes
Source
Original Reference(s)
Cyp2c66Mousecaffeine pharmacokinetics pathway  ISOCYP2C9 (Homo sapiens)10402751 SMPDBSMP:00028
Cyp2c66Mousecelecoxib pharmacodynamics pathway  ISOCYP2C9 (Homo sapiens)10402751 SMPDBSMP:00096
Cyp2c66Mousecelecoxib pharmacokinetics pathway  ISOCYP2C9 (Homo sapiens)10402751 SMPDBSMP:00644
Cyp2c66Mouseclopidogrel pharmacodynamics pathway  ISOCYP2C9 (Homo sapiens)10402751 SMPDBSMP:00260
Cyp2c66Mouseclopidogrel pharmacokinetics pathway  ISOCYP2C9 (Homo sapiens)10402751 SMPDBSMP:00610
Cyp2c66Mousecyclophosphamide pharmacodynamics pathway  ISOCYP2C9 (Homo sapiens)10402751 SMPDBSMP:00447
Cyp2c66Mousecyclophosphamide pharmacokinetics pathway  ISOCYP2C9 (Homo sapiens)10402751 SMPDBSMP:00604
Cyp2c66Mousedoxepin pharmacokinetics pathway  ISOCYP2C9 (Homo sapiens)10402751 SMPDBSMP:00641
Cyp2c66Mousefluoxetine pharmacodynamics pathway  ISOCYP2C9 (Homo sapiens)10402751 SMPDBSMP:00426
Cyp2c66Mousefluoxetine pharmacokinetics pathway  ISOCYP2C9 (Homo sapiens)10402751 SMPDBSMP:00646
Cyp2c66Mouseibuprofen pharmacodynamics pathway  ISOCYP2C9 (Homo sapiens)10402751 SMPDBSMP:00086
Cyp2c66Mouseibuprofen pharmacokinetics pathway  ISOCYP2C9 (Homo sapiens)10402751 SMPDBSMP:00590
Cyp2c66Mouseifosfamide pharmacodynamics pathway  ISOCYP2C9 (Homo sapiens)10402751 SMPDBSMP:00448
Cyp2c66Mouseifosfamide pharmacokinetics pathway  ISOCYP2C9 (Homo sapiens)10402751 SMPDBSMP:00605
Cyp2c66Mouseneviparine pharmacokinetics pathway  ISOCYP2C9 (Homo sapiens)10402751 SMPDBSMP:00642
Cyp2c66Mousephenytoin pharmacodynamics pathway  ISOCYP2C9 (Homo sapiens)10402751 SMPDBSMP:00327
Cyp2c66Mouserosiglitazone pharmacokinetics pathway  ISOCYP2C9 (Homo sapiens)10402751 SMPDBSMP:00653
Cyp2c66Mousesorafenib pharmacokinetics pathway  ISOCYP2C9 (Homo sapiens)10402751 SMPDBSMP:00648
Cyp2c66Mousevalproic acid pharmacokinetics pathway  ISOCYP2C9 (Homo sapiens)10402751 SMPDBSMP:00635
1 to 19 of 19 rows

Imported Annotations - KEGG (archival)

Object Symbol
Species
Term
Qualifier
Evidence
With
Reference
Notes
Source
Original Reference(s)
Cyp2c66Mousearachidonic acid metabolic pathway  IEA 6907045 KEGGmmu:00590
Cyp2c66Mouselinoleic acid metabolic pathway  IEA 6907045 KEGGmmu:00591
Cyp2c66Mouseretinol metabolic pathway   IEA 6907045 KEGGmmu:00830

1 to 14 of 14 rows
#
Reference Title
Reference Citation
1. Cytochrome P450 CYP2C19 genotypes in Nigerian sickle-cell disease patients and normal controls. Babalola CP, etal., J Clin Pharm Ther. 2010 Aug;35(4):471-7. doi: 10.1111/j.1365-2710.2009.01122.x.
2. Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. Lee CR, etal., FASEB J. 2010 Oct;24(10):3770-81. doi: 10.1096/fj.10-160119. Epub 2010 May 21.
3. Polymorphisms of CYP2C19 gene are associated with the efficacy of thalidomide based regimens in multiple myeloma. Li Y, etal., Haematologica. 2007 Sep;92(9):1246-9. Epub 2007 Aug 1.
4. Phenobarbital-induced severe cutaneous adverse drug reactions are associated with CYP2C19*2 in Thai children. Manuyakorn W, etal., Pediatr Allergy Immunol. 2013 May;24(3):299-303. doi: 10.1111/pai.12058. Epub 2013 Apr 3.
5. Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation. Melanson SE, etal., Am J Hematol. 2010 Dec;85(12):967-71. doi: 10.1002/ajh.21889.
6. Long-Term Loss of Response in Proton Pump Inhibitor-Responsive Esophageal Eosinophilia Is Uncommon and Influenced by CYP2C19 Genotype and Rhinoconjunctivitis. Molina-Infante J, etal., Am J Gastroenterol. 2015 Nov;110(11):1567-75. doi: 10.1038/ajg.2015.314. Epub 2015 Sep 29.
7. OMIM Disease Annotation Pipeline OMIM Disease Annotation Pipeline
8. KEGG Annotation Import Pipeline Pipeline to import KEGG annotations from KEGG into RGD
9. SMPDB Annotation Import Pipeline Pipeline to import SMPDB annotations from SMPDB into RGD
10. ClinVar Automated Import and Annotation Pipeline RGD automated import pipeline for ClinVar variants, variant-to-disease annotations and gene-to-disease annotations
11. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
12. Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease. Smith HE, etal., Pharmacogenet Genomics. 2008 Nov;18(11):943-53. doi: 10.1097/FPC.0b013e32830e1e16.
13. No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma. Vangsted AJ, etal., BMC Cancer. 2010 Aug 4;10:404. doi: 10.1186/1471-2407-10-404.
14. CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity. Zandvliet AS, etal., Clin Cancer Res. 2007 May 15;13(10):2970-6.
1 to 14 of 14 rows
PMID:10349636   PMID:11042159   PMID:11076861   PMID:11217851   PMID:12466851   PMID:12477932   PMID:16141072   PMID:16141073   PMID:21677750   PMID:21873635   PMID:24029230  



Cyp2c66
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCm391939,102,342 - 39,175,200 (+)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl1939,102,342 - 39,175,516 (+)EnsemblGRCm39 Ensembl
GRCm381939,113,898 - 39,186,756 (+)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl1939,113,898 - 39,187,072 (+)EnsemblGRCm38mm10GRCm38
MGSCv371939,188,388 - 39,261,246 (+)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv361939,178,942 - 39,240,067 (+)NCBIMGSCv36mm8
Celera1939,916,729 - 39,978,061 (+)NCBICelera
Cytogenetic Map19C3NCBI
cM Map1933.75NCBI
Cyp2c66
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCr81246,490,888 - 246,582,199 (+)NCBIGRCr8
mRatBN7.21237,078,517 - 237,169,841 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1237,078,517 - 237,169,650 (+)EnsemblmRatBN7.2 Ensembl
Rnor_6.01258,283,655 - 258,299,904 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1147,260,830 - 147,272,006 (-)NCBIRnor6.0rn6Rnor6.0
Rnor_5.01265,735,409 - 265,749,997 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
Celera1234,163,008 - 234,440,322 (+)NCBICelera
Cytogenetic Map1q53NCBI

.

.
Variants in Cyp2c66
1139 total Variants

1 to 10 of 124 rows
Name
Type
Condition(s)
Position(s)
Clinical significance
GRCh38/hg38 18p11.32-11.21(chr18:148963-13715860)x1 copy number loss See cases [RCV000051027] Chr18:148963..13715860 [GRCh38]
Chr18:148963..13715859 [GRCh37]
Chr18:138963..13705859 [NCBI36]
Chr18:18p11.32-11.21		 pathogenic
GRCh38/hg38 18p11.32-11.21(chr18:148963-14081888)x3 copy number gain Developmental Delay and additional significant developmental and morphological phenotypes referred for genetic testing [RCV000051153]|Developmental delay and additional significant developmental and morphological phenotypes referred for genetic testing [RCV000051153]|See cases [RCV000051153] Chr18:148963..14081888 [GRCh38]
Chr18:148963..14081887 [GRCh37]
Chr18:18p11.32-11.21		 pathogenic
GRCh38/hg38 18p11.32-q11.1(chr18:53345-20948503)x3 copy number gain See cases [RCV000052504] Chr18:53345..20948503 [GRCh38]
Chr18:53345..18528464 [GRCh37]
Chr18:43345..16782462 [NCBI36]
Chr18:18p11.32-q11.1		 pathogenic
GRCh38/hg38 18p11.32-q23(chr18:148763-80252290)x3 copy number gain See cases [RCV000052507] Chr18:148763..80252290 [GRCh38]
Chr18:148763..78010173 [GRCh37]
Chr18:138763..76111164 [NCBI36]
Chr18:18p11.32-q23		 pathogenic
GRCh38/hg38 18p11.32-11.21(chr18:148963-14081888)x1 copy number loss See cases [RCV000051154] Chr18:148963..14081888 [GRCh38]
Chr18:148963..14081887 [GRCh37]
Chr18:138963..14071887 [NCBI36]
Chr18:18p11.32-11.21		 pathogenic
GRCh38/hg38 18p11.32-q23(chr18:148963-80252149)x3 copy number gain See cases [RCV000051048] Chr18:148963..80252149 [GRCh38]
Chr18:148963..78010032 [GRCh37]
Chr18:138963..76111023 [NCBI36]
Chr18:18p11.32-q23		 pathogenic
GRCh38/hg38 18p11.32-11.21(chr18:1919684-15325188)x3 copy number gain See cases [RCV000052535] Chr18:1919684..15325188 [GRCh38]
Chr18:1919685..15325187 [GRCh37]
Chr18:1909685..15315187 [NCBI36]
Chr18:18p11.32-11.21		 pathogenic
GRCh38/hg38 18p11.31-11.21(chr18:3389362-14082029)x3 copy number gain See cases [RCV000052536] Chr18:3389362..14082029 [GRCh38]
Chr18:3389360..14082028 [GRCh37]
Chr18:3379360..14072028 [NCBI36]
Chr18:18p11.31-11.21		 pathogenic
GRCh38/hg38 18p11.21(chr18:13298775-14082029)x3 copy number gain See cases [RCV000052540] Chr18:13298775..14082029 [GRCh38]
Chr18:13298774..14082028 [GRCh37]
Chr18:13288774..14072028 [NCBI36]
Chr18:18p11.21		 pathogenic
GRCh38/hg38 18p11.32-11.21(chr18:10001-15380684)x3 copy number gain See cases [RCV000052499] Chr18:10001..15380684 [GRCh38]
Chr18:10001..15380683 [GRCh37]
Chr18:1..15370683 [NCBI36]
Chr18:18p11.32-11.21		 pathogenic
1 to 10 of 124 rows

Predicted Target Of
Summary Value
Count of predictions:510
Count of miRNA genes:349
Interacting mature miRNAs:390
Transcripts:ENSMUST00000087234, ENSMUST00000146494
Prediction methods:Miranda, Rnahybrid
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/).
For more information about miRGate, see PMID:25858286 or access the full paper here.


1 to 10 of 30 rows
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD ID
Symbol
Name
LOD
P Value
Trait
Sub Trait
Chr
Start
Stop
Species
13506250Renmq1_mrenal mercury accumulation QTL 1 (mouse)192738559461385705Mouse
10412251Mnp_mmodifier of Niemann Pick type C1 (mouse)Not determined192023431454234461Mouse
1302170Tanidd1_mtally ho associated non-insulin dependednt diabetes mellitus 1 (mouse)Not determined193675259761420004Mouse
1301466T2dm2_mtype 2 diabetes mellitus 2 (mouse)Not determined193837605061420004Mouse
11039522Tbbr4_mTrypanosoma brucei brucei response 4 (mouse)19531332639313470Mouse
1301336Alcp23_malcohol preference locus 23 (mouse)Not determined191591260749912719Mouse
1558876W3q14_mweight 3 weeks QTL 14 (mouse)Not determined192231332653911504Mouse
1302019Pgia23_mproteoglycan induced arthritis 23 (mouse)Not determined19978745343787602Mouse
1301633Alcp24_malcohol preference locus 24 (mouse)Not determined191591260749912719Mouse
14928311Manh85_mmandible shape 85 (mouse)191191478945914789Mouse

1 to 10 of 30 rows






Ensembl Acc Id: ENSMUST00000087234   ⟹   ENSMUSP00000084487
Type: CODING
Position:
Mouse AssemblyChrPosition (strand)Source
GRCm39 Ensembl1939,102,342 - 39,175,200 (+)Ensembl
GRCm38.p6 Ensembl1939,113,898 - 39,186,756 (+)Ensembl
Ensembl Acc Id: ENSMUST00000146494   ⟹   ENSMUSP00000120397
Type: CODING
Position:
Mouse AssemblyChrPosition (strand)Source
GRCm39 Ensembl1939,102,354 - 39,175,516 (+)Ensembl
GRCm38.p6 Ensembl1939,113,910 - 39,187,072 (+)Ensembl
RefSeq Acc Id: NM_001011707   ⟹   NP_001011707
RefSeq Status: PROVISIONAL
Type: CODING
Position:
Mouse AssemblyChrPosition (strand)Source
GRCm391939,102,342 - 39,175,200 (+)NCBI
GRCm381939,113,898 - 39,186,756 (+)ENTREZGENE
MGSCv371939,188,388 - 39,261,246 (+)RGD
Celera1939,916,729 - 39,978,061 (+)RGD
cM Map19 ENTREZGENE
Sequence:
Protein RefSeqs NP_001011707 (Get FASTA)   NCBI Sequence Viewer  
GenBank Protein AAI47820 (Get FASTA)   NCBI Sequence Viewer  
  AAI47825 (Get FASTA)   NCBI Sequence Viewer  
  AAP55508 (Get FASTA)   NCBI Sequence Viewer  
  EDL41815 (Get FASTA)   NCBI Sequence Viewer  
Ensembl Protein ENSMUSP00000084487
  ENSMUSP00000084487.3
  ENSMUSP00000120397.2
RefSeq Acc Id: NP_001011707   ⟸   NM_001011707
- Peptide Label: precursor
- UniProtKB: Q5GLZ0 (UniProtKB/TrEMBL),   Q5GLZ1 (UniProtKB/TrEMBL)
- Sequence:
Ensembl Acc Id: ENSMUSP00000084487   ⟸   ENSMUST00000087234
Ensembl Acc Id: ENSMUSP00000120397   ⟸   ENSMUST00000146494

Name Modeler Protein Id AA Range Protein Structure
AF-Q5GLZ0-F1-model_v2 AlphaFold Q5GLZ0 1-490 view protein structure

RGD ID:13679422
Promoter ID:EPDNEW_M23860
Type:multiple initiation site
Name:Cyp2c66_1
Description:Mus musculus cytochrome P450, family 2, subfamily c, polypeptide66 , mRNA.
SO ACC ID:SO:0000170
Source:EPDNEW (Eukaryotic Promoter Database, http://epd.vital-it.ch/)
Experiment Methods:Single-end sequencing.
Position:
Mouse AssemblyChrPosition (strand)Source
GRCm381939,113,910 - 39,113,970EPDNEW


1 to 25 of 25 rows
Database
Acc Id
Source(s)
Ensembl Genes ENSMUSG00000067229 Ensembl, ENTREZGENE, UniProtKB/TrEMBL
Ensembl Transcript ENSMUST00000087234 ENTREZGENE
  ENSMUST00000087234.3 UniProtKB/TrEMBL
  ENSMUST00000146494.2 UniProtKB/TrEMBL
Gene3D-CATH 1.10.630.10 UniProtKB/TrEMBL
InterPro Cyt_P450 UniProtKB/TrEMBL
  Cyt_P450_CS UniProtKB/TrEMBL
  Cyt_P450_E_grp-I UniProtKB/TrEMBL
  Cyt_P450_sf UniProtKB/TrEMBL
  Cytochrome_P450_fam2 UniProtKB/TrEMBL
KEGG Report mmu:69888 UniProtKB/TrEMBL
MGD MGI:1917138 ENTREZGENE
NCBI Gene 69888 ENTREZGENE
PANTHER CYTOCHROME P450 2C9 UniProtKB/TrEMBL
  CYTOCHROME P450 508A4-RELATED UniProtKB/TrEMBL
Pfam p450 UniProtKB/TrEMBL
PharmGKB CYP2C8 RGD
PhenoGen Cyp2c66 PhenoGen
PRINTS EP450I UniProtKB/TrEMBL
  P450 UniProtKB/TrEMBL
PROSITE CYTOCHROME_P450 UniProtKB/TrEMBL
Superfamily-SCOP Cytochrome_P450 UniProtKB/TrEMBL
UniProt D6RJ25_MOUSE UniProtKB/TrEMBL
  Q5GLZ0 ENTREZGENE, UniProtKB/TrEMBL
  Q5GLZ1 ENTREZGENE
1 to 25 of 25 rows